Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Inclusion Criteria: * Confirmed diagnosis of MCL with CD20 and cyclin D1 positivity or cyclin D1 negative MCL classic histology in tissue biopsy. Patients must have never received any prior therapy for their disease. Patients have been observed for 3 - 6 months with no progression as per imaging assessments * High risk smoldering MCL (i.e. patients without any B symptoms or any symptoms related to MCL warranting immediate systemic therapy) with at least one or more of these eligibility criteria: * Ki-67 of 15-30% (Ki-67% from involved tissue not bone marrow \[BM\], unless confirmed by pathologist), * White blood cells (WBC) 15-30k * Lymph node size 3-5 cm in diameter * Complex karyotype * TP53 mutated or wild type and/or del17p (fluorescence in situ hybridization \[FISH\]% 10-50%) * MYC positive MCL. MYC positive (either by FISH or by immunohistochemistry \[IHC\] and confirmed by pathology at MD Anderson Cancer Center \[MDACC\]) * Presence of either or KMT2D, BIRC3, NOTCH2, NSD2 or more than one mutation in the initial next generation sequencing (NGS) panel testing are allowed * Understand and voluntarily sign an institutional review board (IRB)-approved informed consent form * Age \>= 18 years at the time of signing the informed consent * Patients should in general have bi-dimensional measurable disease with their biggest tumor less than or equal to 5 cm. (Bone marrow or gastrointestinal \[GI\] only involvement is acceptable) * Eastern Cooperative Oncology Gr…